First Description and Search for Aetiology

A number of the characteristics of the disease known today as sarcoidosis were first described in the 18th and 19th centuries. In 1798 erythema nodosum was described by William, and as early as in 1882 the microscopical characteristics of epitheloid and giant cells were reported by Tenneson. In 1889 Ernest Besnier, a French dermatologist, presented a 34-year-old man with lesions on the face and upper limbs. He considered the facial changes related to lupus erythematosus, an autoimmune disorder characterized by facial skin lesions. The term ‘lupus pernio’ shaped by Besnier is still used today to describe facial skin lesions of sarcoidosis patients.

Sarcoidosis is regarded today as a systemic disorder which can affect virtually all organs of the body. This view is based on the work of Kuznitzky, Bittorf and Schaumann. In 1914, Jörgen Schaumann, a Swedish dermatologist, wrote a prize-winning essay on lupus pernio, in which he expressed the view that Besnier’s lupus pernio and Boeck’s multiple sarcoi ds are manifestations of the same disease, that this disease might also involve the lymph nodes, the mucosa of the nose, the tonsils, the bones and the lungs, and that all of these manifestations are characterized by a histological pattern which he summarized as a ‘tuberculoid granulomatous process’. Schaumann suggested the term ‘lymphogranulomatosis benigna’ for the disease since it appears to involve predominantly the lymphatic system. In this essay published in 1934 he identified radiographic changes of the bone due to sarcoidosis and typical histological changes in different organs, thus demonstrating that an affection of the skin is not mandatory for the diagnosis of sarcoidosis.

As early as 1905 Boeck described sarcoidosis as ‘a bacillary infectious disease, which is either identical with tuberculosis or closely related to it’, however, proof of this hypothesis remains elusive. Nevertheless, there is an ongoing discussion of this question. Using methods of histology and molecular biology the presence of acid fast rods, mycobacterial DNA and mycobacterial rRNA has been demonstrated in sarcoidosis. However, other investigators have not been able to reproduce these findings and, based on the assumption that per 10^6 host cells of established lesions more than 15 organisms are required to play a pathogenetic role, it has been concluded that Mycobacterium tuberculosis, other mycobacteria, or closely related organisms are not involved in sarcoidosis, recently reviewed by Mangiapan and Hance.

In addition, a number of other infectious organisms have been claimed to be capable of inducing sarcoidosis. For example, mycoplasma-like organisms or Borrelia burgdorferi have recently been proposed as a possible cause of sarcoidosis, however, for the latter, data obtained by our group do not support this hypothesis.

Epidemiological data and similarities with other infectious diseases support the hypothesis that sarcoidosis is induced by an infectious agent. Seasonal clustering of sarcoidosis in the months of June and July, time and space clusters, an increased incidence in health workers, and the transmission of sarcoidosis by transplants have been observed and further support the hypothesis of transmissible agents inducing sarcoidosis. Most interestingly, there are numerous reports of sarcoidosis patients who suffered from a relapse of sarcoidosis in a transplanted lung despite receiving immunosuppressive therapy. Vice versa a patient receiving a lung from a donor who had a spontaneous remission of sarcoidosis in the past was observed to develop sarcoid-like lesions. These observations suggest...
that the aetiological agent hides within the lung and/or in other compartments of the body. Despite the efforts made to elucidate the aetiology the statement made by Longcope and Frei- mann in 1952 is still true: ‘The aetiology of sarcoidosis is still obscure, the relation which it bears to tuberculosis or possibly other forms of granulomata remains a matter of contention and the conclusive demonstration of its presence rests entirely upon the histological structure of the lesions which it produces. ... The most telling contribution that could be made to our knowledge of this peculiar condition would be the discovery of its aetiology.’

**Definition, Natural Course of the Disease, and Treatment**

An evaluation of transbronchial or open lung biopsies of patients in the early stage of disease supports the clinical diagnosis by demonstrating the typical findings of noncaseating granulomas within the alveolar, bronchial and vascular walls. These granulomas are diffusely scattered throughout the lung parenchyma. They are usually of varying age, ranging from highly cellular lesions to collections with diminishing cellularity, some fibrosis, and progressive hyalinization. Two characteristic zones can be seen in a typical, well-developed sarcoid granuloma: (i) a central zone or follicle which is tightly packed with cells, composed primarily of macrophages, multinucleated giant cells, and epitheloid cells; and (ii) a peripheral zone containing loosely arranged cells like a collar of lymphocytes, monocytes, and fibroblasts (Fig. 1).

Although many microscopic features may suggest sarcoidosis, the epitheloid granulomas, especially in their earlier stages, are indistinguishable from those of other idiopathic granulomatous disorders.

Thus, sarcoidosis is best defined in histopathological terms as ‘a disease characterized by the presence in all of several affected organs and tissues of noncaseating epitheloid-cell granulomas, proceeding either to resolution or to conversion into hyaline connective tissue’. The clinical diagnosis, however, can only be supported by typical histopathological findings. Pathognomonic criteria or a diagnostic ‘golden standard’ are absent.

Most patients with diagnosed sarcoidosis will undergo clinical and radiological resolution of the disease over a period ranging from several months to a few years. A few of them develop a progressive form of the disease which may result in death. Only rough estimates of the mortality of untreated sarcoidosis are available. If untreated a mortality of about 5% is estimated.

The aetiology of sarcoidosis remains unknown and, therefore, no specific treatment is possible. Fortunately, many patients will not require treatment because the symptoms are not disabling and frequently remit spontaneously. Prompt initiation of corticosteroid therapy, however, is indicated when granulomas cause dysfunction in vital organs or when the inflammation is particularly disabling or when disfiguring skin lesions emerge.

**FIG. 1.** Light photomicrograph of a typical non-caseating granuloma with multinucleated giant cells.
Bronchoalveolar Lavage

Although the technique of bronchoalveolar lavage (BAL) was introduced in the 1920s, the first article describing pulmonary alveolar lavage as a method for harvesting large numbers of macrophages from the rabbit lung was not published until 1961 by Myrvik et al. Finley et al. have demonstrated that BAL can be safely performed in humans using a wedged catheter. With the introduction of the fibre-optic bronchoscope into clinical medicine by Ikeda et al. BAL has become widely used for clinical investigations. The observation of characteristic changes in the cytology of BAL in interstitial lung diseases first reported by Hunninghake in 1971 gave rise to a large number of detailed investigations of pulmonary immunology in health and disease. The findings obtained by various researchers over the past 15 years form the basis of a concept of the immunopathogenesis of sarcoidosis discussed in the following.

Ultrastructural Changes

In addition to granulomas, the morphological appearance of sarcoid of the lung has many of the features typical of mild interstitial lung diseases. Early in the disease unspecific ultrastructural lesions of the air–blood barrier can be observed, frequently even in areas of the lung which appear normal using light microscopy. The alveolar walls are expanded. The type I epithelial cells of the alveoli are injured denuding the basal membrane of a number of alveoli. These defects are covered by cuboidal cells, primarily pneumocytes type II. In other areas, the endothelial cells are damaged and capillaries are replaced by connective tissue. In rare cases a fibroblast proliferation in the alveolar and/or bronchial walls can be observed; it is these cases in which various amounts of dense fibrosis are observed replacing the normal parenchymal structures, thus hindering the gas exchange.

Similar lesions can be observed in various clinical or experimental conditions including asbestosis, idiopathic pulmonary fibrosis, pulmonary histiocytosis X, systemic sclerosis with lung involvement, early stages of ARDS, X-ray irradiation, paraquat, bleomycin, or 3-methylindole toxicity, and exposure to nitrogen or oxygen. The occurrence of similar reactions in such different conditions supports the concept of a common pattern of pulmonary response to diverse injuries.

A sequela of the early damage to the morphology of the basal membrane in interstitial lung diseases is a change in the composition of the alveolar lining fluid. Albumin and glucose are found at high concentrations in the alveolar lining fluid of patients with sarcoidosis which may be due to leakage in the basal membrane or to a defect of the epithelial cells resulting in a decreased transmembrane transportation rate from the alveolar lumen back to the interstitium. These changes correlate with various parameters of inflammation, e.g. cellularity of BAL. In addition, dramatic changes in the composition of the surfactant are observed in interstitial lung diseases, indicating an alteration in type II epithelial cells which produce the surfactant proteins and phospholipids. These proteins are now recognized to exhibit immunomodulatory functions, either anti- or pro-inflammatory in nature. The pathophysiological role of the interaction of epithelial lining fluid components and cells of the lower respiratory tract are unknown and represent a new and exciting field of research.

Alveolar Macrophages

Alveolar macrophage activation in sarcoidosis: Due to a considerable increase in lavage cellularity, the absolute number of alveolar macrophages expands in sarcoidosis while the relative number decreases. The percentage of alveolar macrophages with monocytic appearance is elevated in sarcoidosis, suggesting a recent immigration of monocytic precursors of alveolar macrophages from the blood. A number of cytokines chemotactic for monocytes, e.g. interleukin-1 (IL-1), tumour necrosis factor α (TNFα), macrophage inflammatory protein-1α (MIP-1α), and colony stimulating factors, are produced by alveolar cells in the course of inflammatory reactions of sarcoidosis and other interstitial lung diseases, supporting the notion of monocyte immigration. However, those markers characteristic of a monocytic immunophenotype can be acquired by alveolar macrophages in the course of activation. Thus, the question of monocyte immigration is not yet settled.

The activated state of these cells has been demonstrated on the basis of their spontaneous in vitro production of IL-1. Results of the first report could not be reproduced by other investigators, although IL-1-mRNA was found in these cells. A number of researchers have subsequently repeated these experiments and observed IL-1 in the supernatants of alveolar macrophages of patients with active sarcoidosis. In addition, IL-1 inhibitors and IL-1 receptor antagonist were identified in BAL fluid and cell culture supernatants, thus providing at least a partial explanation of the conflicting results. Mediators of Inflammation Vol 5 1996 243
Since the publication of the above results a number of monokines, i.e. TNFα, IL-6, MIP-1α, and monocyte chemotactic protein-1, have been identified as being released by alveolar macrophages in the course of sarcoidosis.52,58-60,65,64 Analysing the release of TNFα and IL-6 by these cells revealed that the activation of the cells of the monocyte/macrophage lineage is compartmentalized, i.e. alveolar macrophages release these mediators spontaneously, whereas the corresponding cells of the peripheral blood are quiescent (Table 1).60,63 In sarcoidosis TNFα is released at high concentrations at the place of the inflammatory reaction, however, a corresponding cachectin effect is absent in most patients, giving rise to the hypothesis that TNFα-binding or neutralizing proteins or counteracting cytokines are simultaneously released. The fact that IL-6 proved in in vitro experiments to be capable of down-regulating the release of other pro-inflammatory cytokines, such as TNFα and IL-1,65 led to the hypothesis that in vivo IL-6 might be able of dampening the cachectis of sarcoidosis or even of inducing a spontaneous regression of the disease. However, the coexpression of TNFα and IL-6 in active sarcoidosis and the absence of IL-6 release of BAL cells from patients with inactive disease demonstrate (Table 1) that IL-6 does not exert detectable anti-inflammatory actions in sarcoidosis. Furthermore, soluble TNF-receptors (sTNF-R) may well be capable of counteracting TNFα effects.66 Preliminary results obtained by our group demonstrate the presence of increased sTNF-R serum levels correlating with alveolar macrophage TNFα release and might, therefore, play a role in dampening the cachectin effects of TNFα (Fitschen, unpublished results). However, increased levels of both forms of the sTNF-R can be found in the alveolar lining fluid of patients with sarcoidosis and numerous interstitial and obstructive lung diseases55 making it unlikely that they play a specific role in the immunopathogenesis of sarcoidosis.

Kinetic studies on the transcriptional level of the TNFα-gene revealed that maximal mRNA transcription is reached within 2 h after stimulation. Cytoplasmic TNFα was detected as early as 1 h after stimulation, culminating during the next 2 h to be followed by a decline.67 Similar experiments with sarcoid alveolar macrophages revealed the transcription of the TNFα-gene at the time of BAL and its down-regulation during the next 24 h in cell culture.60 Thus, the heightenened spontaneous TNFα release seen in active sarcoidosis is the consequence of an in vivo activation step just prior to the removal of the cells from the lung indicating that the eliciting agent resides in the lower respiratory tract. In parallel to the findings on the transcriptional level the highest amount of TNFα is released during the first 3 h of in vitro culture followed by a sharp decline.60 Therefore, it can be concluded that TNFα release is regulated in a physiological manner in those cells and that the putative agent causing sarcoidosis does not interfere with the regulation of the TNFα release neither on the transcriptional nor on the post-transcriptional level.

Subsequent cytokine studies were extended to

<table>
<thead>
<tr>
<th>Cells</th>
<th>Spontaneous release of IL-6 (pg/ml/10^6 cells, median, range)</th>
<th>Spontaneous release of TNFα (pg/ml/10^6 cells, median, range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alveolar macrophages active sarcoidosis</td>
<td>1012 (n = 16), 104-3264 (n = 46)</td>
<td>1156 (n = 22), 100-17362 (n = 41)</td>
</tr>
<tr>
<td>Alveolar macrophages inactive sarcoidosis</td>
<td>0-977 (n = 12), 0-1643 (n = 27)</td>
<td>388 (n = 22), 0-1011 (n = 26)</td>
</tr>
<tr>
<td>Alveolar macrophages controls**</td>
<td>141 (n = 12), 0-804 (n = 26)</td>
<td>291 (n = 22), 0-4-122 (n = 41)</td>
</tr>
<tr>
<td>Peripheral blood mononuclear cells active</td>
<td>144 (n = 22), 0-312 (n = 41)</td>
<td>377 (n = 22), 0-4-122 (n = 26)</td>
</tr>
<tr>
<td>Peripheral blood mononuclear cells</td>
<td>77 (n = 19), 0-153 (n = 24)</td>
<td>476 (n = 22), 0-943 (n = 31)</td>
</tr>
<tr>
<td>inactive sarcoidosis</td>
<td>91 (n = 16), 0-124 (n = 23)</td>
<td>306 (n = 22), 0-887 (n = 23)</td>
</tr>
</tbody>
</table>

* Inflammatory activity of disease was judged on the basis of clinical symptoms and organ dysfunction,26 data from Refs 60 and 63, supplemented with unpublished data.
** Patients undergoing diagnostic bronchoscopy being retrospectively free of any inflammatory or malignant lung disease served as controls.
include the interstitium and the lymph node showing a simultaneous activation of alveolar macrophages, interstitial macrophages, and macrophages in the granulomas. In general, interstitial macrophages differ from alveolar macrophages in the relative expression of immunological functions. The latter are poor accessory cells and IL-1 producers, but appear to be better equipped to clear infectious agents from the lower respiratory tract, whereas interstitial macrophages have higher accessory and immunoregulatory capabilities. However, the interpretation of these experiments has been complicated by possible stimulations via minor histocompatibility antigens or by intrinsic activities of autologous sarcoid T-cells present in the test. In a different cell culture system using a method insensitive to histo-incompatibilities, sarcoid alveolar macrophages were shown to express increased accessory functions mediated by adhesion molecules, e.g. CD80. 

**Down-regulation of alveolar macrophage activity:** The characteristics of the stimulated alveolar macrophages described above suggest an activation in the course of a normal immune response. In approximately 60% of all sarcoid patients spontaneous regression of the disease is observed. Therefore, down-regulating mechanisms inducing spontaneous remission should be present in sarcoidosis.

Transforming growth factor-β (TGFβ) is a member of the superfamily of ubiquitous regulatory proteins which are necessary for cell growth, cell differentiation, and regulation of extracellular matrix production. Growing evidence also confirms its role as an immunomodulator, exhibiting pro-inflammatory and anti-inflammatory properties. Interleukin-10 is another potent inhibitor of monocyte/macrophage- and T-cell-activation. It inhibits the cytokine production and proliferation of human monocytes and T cells and the TNFα release of human pulmonary dendritic cells. CD4+ Th0 and CD4+ Th2 cells are the major IL-10 producing cells, while macrophages and monocytes also release IL-10 although to a lesser extent.

IL-10 is capable of suppressing the release of TNFα and IL-1 by LPS activated alveolar macrophages in a dose-dependent manner. IL-6 release, however, is not affected by IL-10 (Fig. 2). TNFα and IL-1 are two key mediators in sarcoid alveolitis required for the induction and maintenance of granulomata. Thus, IL-10 is a candidate cytokine for the induction of the spontaneous regression of sarcoidosis. Due to its TNFα suppressing capabilities high levels of IL-10 are anticipated in patients with low TNFα release and vice versa. As expected, in cell culture supernatants of alveolar macrophages of sarcoid patients containing high concentrations of TNFα counteracting IL-10 could not be found. In those supernatants with low concentrations of TNFα, however, in which an anti-inflammatory action has to be assumed IL-10 was absent indicating that the mechanism controlling the alveolitis does not employ this mediator.

In an experimental protocol as described above for IL-10 a suppressive effect of TGFβ on LPS-activated, human alveolar macrophage cytokine release could not be detected. Employing lower concentrations of LPS, however, disclosed a dose-dependent suppressive effect of TGFβ on this type of cells. 100 ng/ml or 10 ng/ml of LPS are to potent stimulatory signals to be counteracted by TGFβ. Stimulation by 1 ng LPS/ml or in vivo stimulations resulting in an in vitro TNFα release result in an activation which can be down-regulated by TGFβ. By the presence of 200–1000 pg TGFβ per ml the TNFα release of cells stimulated in such a way was significantly reduced to 65–89% of control cultures without TGFβ (Fig. 3).

In the lung the inactive form of TGFβ is an abundant cytokine and mechanisms activating TGFβ can be observed during alveolitis. The release of proteases and the acidification of the
Sarcoid patients whose BAL cells released low amounts of TGFβ either required corticosteroid therapy (Group I: 677 ± 159 pg/ml) or had evidence of persisting disease when no therapy was administered (Group III: 762 ± 419 pg/ml). In marked contrast, eight out of twelve patients with active disease who had a spontaneous remission of disease within the following six months (Group II: 1422 ± 215 pg/ml) exhibited elevated TGFβ release by BAL cells. In these patients TGFβ release differed significantly from that recorded in Groups I, III and controls (II versus III: p < 0.04, II versus I and II versus control: p < 0.004). Most interestingly, in 5/5 patients under therapy elevated TGFβ release was also observed (Group IV, 1698 ± 244 pg/ml) and differed significantly from Groups I, III and controls (p < 0.04 for all comparisons, Fig. 4).

In addition, IL-2 concentrations were estimated in BAL cell culture supernatants of the four study groups. In Group I (requiring therapy) and in Group II (spontaneous remission) elevated IL-2 levels (9.8 ± 4.5 U/ml (n = 12) and 2 ± 1.4 U/ml (n = 5) respectively) without statistically significant differences were observed. In Group III (persistent disease) 3/3 patients had undetectable IL-2 levels. In Group IV (receiving corticosteroids), however, 1/3 patients showed an elevated IL-2 release (Fig. 4).

Although pro-inflammatory cytokines are considered to maintain sarcoid alveolitis their presence is not associated with a state of disease requiring therapy if their action is counteracted by an anti-inflammatory mediator such as TGFβ, as can be seen from the difference in the course of the disease between Groups I and II in the above-described study.

Considering the known immunomodulatory effects of TGF β a direct anti-inflammatory action in sarcoid alveolitis seems conceivable. It can function as an autoregulatory lymphokine that limits lymphocyte expansion as it has been demonstrated for T-cells. After mitogen stimulation T-cells express the genes for pro-inflammatory cytokines as well as for TGFβ and accumulate TGFβ protein. However, its release is delayed consistent with a auto-regulatory role in limiting T-cell expansion so that it can dampen the IL-1- and IL-2-responses of T-cells and therefore limit the inflammatory reac-
Sarcoidosis

FIG. 4. Release of TGF-β (upper panel), TNFα and IL-2 (lower panel) by the four groups of sarcoid patients. Cytokines were measured in supernatants of cultured BAL cells (10^6 cells/ml, 24 h) either by bioassay (TGF-β and IL-2) or by ELISA (TNFα). Mean of TGF-β release is significantly elevated in Group II (spontaneous remission) and in Group IV (patients under therapy) indicated by bold lines. In Group I (requiring therapy) and Group III (persisting disease) TGF-β release is below the upper limit of the normal range. TNFα and IL-2 release is elevated in Group I and II whereas it is within the normal range in Groups III and IV. Upper limits of TGF-β, TNFα and IL-2 release derived from seven (TGF-β), 14 (TNFα) and 13 (IL-2) controls are indicated by the arrows (TNFα left, IL-2 right side). Taken from Zissel et al.88

Macrophages can be deactivated by TGFβ and its mode of action is well described. In contrast to IL-10, which promotes degradation of pro-inflammatory cytokine mRNA, TGFβ inhibits post-transcriptional mechanisms in TNFα, IL-1α, and IL-1β production. It does not affect the level of TNFα mRNA, the release of preformed TNFα nor the degradation of TNFα. Thus, TGFβ appears to inhibit translation of TNFα mRNA.7,9

In general, TGFβ enhances monocyte function which is mediated by TGF-receptors expressed in high density by these cells.108 During the process of maturation to macrophages the receptor expression is down-regulated and the ligand binding to the remaining receptors induces deactivating mechanisms108,109 making it feasible that the above described in vitro mechanisms act in vivo.

The patients in Group II of the study described above have a good prognosis and are certainly not under the risk of developing pulmonary fibrosis. High concentrations of TGFβ can, however, be observed in a number of in vitro and experimental situations resulting in fibrosis. Increased collagen synthesis in an animal model of hypersensitivity pneumonitis is associated with heightened TGFβ levels and can be abrogated by anti-TGFβ antiserum.110 In bleomycin-treated mice, a model of pulmonary fibrosis, blocking of TGFβ by antibodies prevents fibrosis as well.111,112 The foregoing data suggest that an increase in TGFβ concentration leads to fibrosis. Supporting this concept in chronic liver disease,113,114 systemic sclerosis,115 pulmonary fibrosis114,116 and a number of other disorders with tissue fibrosis117 such an increase of TGFβ has been identified. However, the response of fibroblasts to TGFβ differs with the state of disease and their expression of receptors for other cytokines like platelet-derived growth factor.118 Fibroblasts of different organs differ in their response to TGFβ, e.g. lung fibroblasts down-regulate and scleroderma skin fibroblasts up-regulate their platelet-derived growth factor receptors whereas normal skin fibroblasts do not modulate this receptor in response to TGFβ.118 These findings are compatible with the concept that TGFβ, hence activated, uses its anti-inflammatory capabilities demonstrated for macrophages,99,119 T- and B-lymphocytes,100,120,121 cell proliferation,122 and cytokine release123 to down-regulate pulmonary inflammation.

A study with inbred mice demonstrated that the susceptibility to the induction of pulmonary fibrosis by bleomycin sulphate is strain dependent. The lungs of bleomycin treated fibrosis susceptible C57BL/6J and fibrosis resistant BALB/cBy mice were analysed for their mRNA expres-
sion level of a panel of cytokines. TGFβ mRNA was found to increase seven-fold after bleomycin treatment in sensitive and three-fold in resistant animals. Analysis of F1 hybrids, which were shown in this report to be sensitive to bleomycin-induced fibrosis, revealed a segregation of a cytokine pattern completely concordant with the segregation of susceptibility phenotypes between the parental and F1 strains, i.e. the expression of IL-6 and TGFβ. This result indicates a possible association between sensitivity to bleomycin-induced fibrosis and inductibility of IL-6. Furthermore, IL-4 and interferon-γ (IFNγ), both products of activated T-cells, have been confirmed to decrease CD14 expression on monocytes/macrophages by decreasing transcription of the CD14 gene. It has been demonstrated that IFNγ is released spontaneously by T-lymphocytes of patients with active sarcoidosis and that elevated levels of circulating IFNγ in serum can be detected in most untreated patients with sarcoidosis.

In this context changes in CD14 expression by macrophages/monocytes and an increase in sCD14 may be expected in sarcoidosis patients. Sarcoid alveolar macrophages were found to express exaggerated levels of surface CD14 and in the alveolar lining fluid its soluble form is increased in active sarcoidosis. Interestingly, a small increase in sCD14 serum levels correlating with neopterin and angiotensin converting enzyme was observed. Unfortunately, the changes in sCD14 serum concentration induced by sarcoid immunopathological mechanisms in vivo are of a magnitude which prevents the exploitation of this phenomenon for clinical purposes.

Neopterin, a small, 250 Da metabolite of the guanosinetriphosphate pathway is released by activated macrophages and monocytes under the control of IFNγ produced by T-cells. As expected, elevated serum levels were found in sarcoidosis and are used to monitor the activity of cells of the macrophage/monocyte lineage in the course of the disease. Interestingly, a correlation between BAL cell TNFα or IL-6 release with serum neopterin could not be observed giving rise to the hypothesis that the elevated neopterin levels are sequelae of cell activations in other body-compartment than the alveolar space, such as lymph nodes providing secreted molecules an easy access to the serum. Nevertheless, serum or urine neopterin concentration proved to be a very useful clinical parameter to probe the activity of the cells of the monocyte/macrophage lineage in the course of sarcoidosis.

It has to be kept in mind that none of the above-mentioned parameters can be used to establish a diagnosis. Elevated levels are found in a number of diseases. Once the diagnosis of sarcoidosis has been made, the inflammatory activity of the immunopathogenetical processes described above can be monitored by the use of these serum parameters.

**T-cells**

*T-cell activation:* Sarcoidosis is associated with an increase in the number of alveolar T-cells, and
a shift to an increase in CD4+ cells within these cells can be observed. In normal BAL up to 20% T-cells with a CD4/CD8 ratio ranging from 1.0 to 3.0 (median 2.2) may be found. Apart from a small number of neutrophils (< 5%) the remaining cells are alveolar macrophages. In some cases of sarcoidosis more than 50% T-cells with a CD4/CD8 ratio > 10 can be observed exhibiting markers of activation, such as increased HLA-DR, VLA-1, and interleukin (IL)-2 receptor expression and capping of the T-cell-antigen receptor.

Without any stimulation in tissue culture these T-cells have been found to release in vitro IL-2. This finding represents the first demonstration of the involvement of IL-2 in the immunopathophysiology of a human disease. In spite of the systemic nature of the disease only the alveolar T-cells—but not those of the peripheral blood—secrete IL-2. Interestingly, the regulation of the transcription of the IL-2 gene appears to be normal indicating a stimulation of the cells in a physiological fashion. This view is supported by the finding of duBois et al. who demonstrated a capping of the T-cell-antigen receptor of alveolar T-cells in sarcoidosis suggesting a recent activation of the cells via this complex. These two phenomena can be observed in cells of the BAL, indicating that the eliciting agent resides in the lung or that activated cells are attracted to the lung as observed in animal models of pulmonary inflammation.

Owing to the fact that the genes of IL-2 and IL-2R are coexpressed the enumeration of IL-2R positive T-cells was considered to be an approach to estimate the number of activated alveolar T-cells. Only a moderate increase in IL-2R+ T-cells was observed, suggesting the presence of a small number of activated cells in the alveolar space or a dysregulation in the expression of the IL-2R. Results obtained by an in vitro study with sarcoid T-cells excluded the latter possibility. Other immunological disorders, e.g. rheumatoid arthritis and multiple sclerosis, also exhibit small increases in IL-2R+ T-cells at the site of inflammation, i.e. the synovial surface and the multiple sclerosis lesions, respectively, thus supporting the above-mentioned finding. However, the milieu of the lower respiratory tract generated by pulmonary epithelial cells type II modulates the reactivity of the T-cells. In the presence of type II epithelial cells activated T-cells become arrested and do not progress in the cell cycle. When leaving this milieu the blockade is reversed, e.g. after migration of the T-cells to the lymph nodes. The described scenario may also apply for sarcoidosis where a lymphocyte proliferation can be observed in sarcoid lymph nodes.

The majority of the findings with regard to sarcoid T-cell response are characteristic of a T-cell mediated response to antigen and are highly suggestive of the presence of a persistent, poorly degradable antigen or antigens. In 1988 a bias towards an increased usage of the Vβ8 region of the T-cell-antigen receptor in sarcoidosis peripheral blood and bronchoalveolar lavage T-lymphocytes was demonstrated, suggesting that T-cells accumulate secondary to external selective pressure, rather than in a random polyclonal fashion or by clonal expansion of one or a few T-cell clones. This observation has been extended showing restricted usage of T-cell antigen receptor Vβ. In bronchoalveolar lavage and lung parenchyma. However, other technical approaches have demonstrated an increased clonality in bronchoalveolar lavage cells without detecting preferred V-region families, leading to the assumption that the major source of T-cells is a polyclonal unspecific accumulation accompanied by a clonal expansion being different in every patient and contributing about 10% of the T-cells. In normals an oligoclonality in the V-region usage of lung T-cell clones compared with blood clones could not be found. In summary the sarcoidosis studies revealed a number Vβ- and Vβ-family selections of the T-cell-antigen receptor in the detected clones, thus supporting the hypothesis of an unspecific stimulus. It can be concluded that the elusive agent or agents eliciting sarcoidosis select T-cell clones in the lung and other involved organs accompanied by an unspecific polyclonal T-cell accumulation as described for normal immune reactions. This concept of compartmentalization is further supported by studies of autoimmune and chronic inflammatory diseases demonstrating a compartmentalized accumulation of T-cells with some restrictions in Vβ-chain gene usage.

The cytokine release by pulmonary lymphocytes is an immunopathological co-determinant of progressing alveolitis. Those patients with high numbers of activated, IL-2 releasing pulmonary T-cells have a high risk of developing pulmonary organ damage requiring corticosteroid therapy. Patients with low numbers of activated BAL lymphocytes or with quiescent cells differ significantly with lower percentages of progressing disease. Thus, parameters of immunopathogenesis can be used to gauge the inflammation of sarcoidosis and to judge prognosis. However, at present this approach requiring tissue culture is not applicable in everyday clinical practice.

In a recent case report, the interesting course of a spontaneous improvement of bronchial asthma was described. Bronchial asthma, a
disease associated with activated T-helper cell (Th)-2-like lymphocytes releasing IL-4 and IL-5 in the lower respiratory tract in combination with a diminished or even missing IL-2 and IFNγ release.\(^{55,177,178}\) came to spontaneous improvement when the patient developed sarcoidosis a disorder characterized by activated Th1-like lymphocytes expressing Th1 cytokines like IL-2\(^{151}\) and IFNγ\(^{136}\) and the absence of Th2 cytokines like IL-4 and IL-5.\(^{55}\) This observation supports the concept that similar to bronchial asthma an imbalance of Th1/Th2 cells might be the underlying immunopathogenetical mechanism which can be tested by identifying the cytokines released by T-cell clones derived from different body-compartments of patients with sarcoidosis.

In comparison with other body-compartments using lymphocytes from BAL or pulmonary parenchyma results in a low cloning efficiency.\(^{179}\) Specific antigen,\(^{180}\) which is not available for sarcoidosis, or unspecific stimulation\(^{181}\) are required to obtain pulmonary T-cell clones. In comparison with blood the analysis of those clones obtained after unspecific stimulation of T-cells from sarcoid patients revealed that in pulmonary parenchyma a shift to Th1 cells can be observed. Moreover, clear-cut Th1, Th2, and Th0 cells were found but represented only a minority of the cells.\(^{181-183}\) Most of the clones expressed the mRNA and secreted Th1 and Th2 cytokines simultaneously suggesting that they are of intermediate types as recently reviewed by Kelso.\(^{184}\) Although only Th1 cytokines can be identified in BAL fluid\(^{55}\) and BAL cell supernatants\(^{151}\) of sarcoidosis patients their T-cells from pulmonary parenchyma or BAL are capable of releasing Th2 cytokines. Furthermore, T-cell clones from BAL disclosed in a rather high percentage clear-cut Th2 cells expressing only IL-4 and IL-5.\(^{182}\) These findings support the hypothesis that in pulmonary sarcoidosis an imbalance of Th1/Th2 cytokines in favour of Th1 cytokines maintains the alveolitis. Th2 cells are present but rendered quiescent\(^{55,182}\) and in case another stimulus activates these Th2 cells the sarcoid alveolitis might be down-regulated.

In this context it is of interest that an analysis on the single cell level of in vitro stimulated BAL T-cells from patients with allergic asthma revealed only a small percentage of cells belonging to the Th2 subset and the majority of cells were releasing IFNγ and IL-4 again demonstrating the frequent appearance of intermediate cytokine patterns in the human system.\(^{185}\) Thus, the Th1/Th0/Th2 cells described in the murine system by Mosmann\(^{186,187}\) contribute only a small percentage of the human T-cells and they represent polarised forms of the spectrum of T-cell cytokine expression used in the regulation of inflammatory reactions.\(^{184,188}\)

In supernatants of BAL cells from sarcoid patients, cytokines preferentially produced by Th1 CD4\(^+\) cells are frequently found\(^{136,153}\) but not the Th2 cytokines IL-4 or IL-10.\(^{55,88,185}\) This indicates that in vivo only active Th1 cells are present although Th2 can be elicited from this cell population in vitro.\(^{182}\) In literature considerations about the influence of co-stimulation on the development of Th1 and Th2 cells are controversial. There is some evidence that co-stimulation by CD80 decreases disease severity in experimental allergic encephalomyelitis by the activation of Th1 cells.\(^{189,190}\) Additionally, it is reported that CD80/CD28 engagement increases the release of IL-2 more than the IL-4 release when the T-cell clones used are able to release both cytokines.\(^{191}\) The preferential activation of Th1 cells observed in BAL of sarcoid patients may thus be a sequela of the exaggerated CD80 expression associated with an increased accessory function of alveolar macrophages in this disease.\(^{75}\)

Another way of down-regulating T-cell activation is accomplished by anti-inflammatory cytokines like IL-10 and TGFβ and in the sarcoidosis study described above a negative correlation between TGFβ release by alveolar cells and their IL-2 release was noted \((r_s = -0.45, p < 0.05, \text{Fig. 5})\).\(^{88}\) Thus, the down-regulating capabilities of TGFβ on activated T-cells found in in vitro and animal studies\(^{76,100-103}\) seem to take place in vivo. In this regard it is of interest that the activation of T-cells via CD28 is resistant to the down-regulation by TGFβ\(^{103}\) explaining the manifestation of chronic disease resistant to immunosuppressive drugs in some patients. In a number of sarcoid patients an increased expression of CD80, the ligand of CD28, on alveolar macrophages has been demonstrated, indicating the

**FIG. 5.** Correlation of TGFβ and IL-2 release of alveolar immune cells in pulmonary sarcoidosis, taken from Zissel et al.\(^{88}\)
possibility of an activation of alveolar T-cells via this pathway.\textsuperscript{75,103} Thus, there is strong evidence that the course of the disease is determined by the mode of T-cell activation and the balance of pro- and anti-inflammatory cytokines in the micromilieu of the lower respiratory tract.

However, there are some findings which indicate that sarcoid T-cells exhibit altered characteristics of activation resulting in a heightened resistance to down-regulating mechanisms. Impaired G-proteins might inhibit adenyl hydrolysis leading to cAMP accumulation, thus maintaining the activated state of the cell.\textsuperscript{192} In sarcoidosis and other lung diseases CD95 (Fas) is expressed by activated BAL T-cells.\textsuperscript{193} Normal binding of the ligand CD70 (Fas-L) results in apoptosis.\textsuperscript{194} Alterations of the Fas/Fas-L system, however, may result in the failure of T-cells to undergo apoptosis and an accumulation of activated T-cells at the sites of disease activity.\textsuperscript{195} Other systems mediating apoptosis, as TNF-receptors with different intracytoplasmatic signal-transducing domains, have been identified and this type of receptors are expressed on the surface of sarcoid alveolar T-cells.\textsuperscript{193,196} Thus, on the basis of the present data it cannot be concluded whether the T-cells become activated in the course of a normal immune response elicited by the unknown agent causing sarcoidosis or if the sarcoid T-cells induce the disease by failure of down-regulation after responding to a normal antigen.

Clinical assessment of T-cell activation: Activated T-cells express an IL-2R 55-kD/75-kD heterodimer on the cell surface and release a soluble form of the 55-kD chain (sIL-2R).\textsuperscript{197,198} sIL-2R can be found in BAL fluid and serum of sarcoidosis patients and it is released by activated alveolar immune cells.\textsuperscript{199–202} In addition to lymphocytes, macrophages are capable of expressing IL-2R upon activation\textsuperscript{203} and it could be demonstrated that up to 50% of activated sarcoid alveolar macrophages exhibit increased numbers of IL-2R.\textsuperscript{204} The relative contribution of lymphocytes and macrophages to the alveolar lining fluid sIL-2R concentration is not known.\textsuperscript{201,204} A major contribution of these cells to the sIL-2R serum level cannot be expected because a leakage of the basal membrane or active transport mechanisms allowing a 55-kD protein to leave the alveolar space have not been observed in sarcoidosis.\textsuperscript{35} In agreement with these findings the sIL-2R serum concentration was found to be independent of alveolar immune cell activation, indicating that these cells are not the main contributors to the exaggerated serum levels of sIL-2R.\textsuperscript{201} Nevertheless, monitoring T-cell activity with sIL-2R serum level reveals an intimate relationship between this parameter and the clinical activity of the disease, providing further evidence for the close linkage between the course of sarcoidosis and the activated state of T-cells (Fig. 6).\textsuperscript{200–202,204,205}

Moreover, those patients with high sIL-2R serum levels indicating a T-cell activation in the course of sarcoidosis exhibit a trend to a favourable spontaneous course of the disease with frequent spontaneous regressions and fewer indications for corticoid therapy.\textsuperscript{206}

Epithelial Cells

Epithelial cells of the lower respiratory tract, especially type II pneumocytes, are integrated in the pulmonary immune response as demonstrated by their constitutive expression of HLA-DR\textsuperscript{207} and their expression of adhesion molecules such as CD54, CD51 and CD49d.\textsuperscript{208,209} Furthermore, TNFα and IL-1, cytokines present in the lower respiratory tract in the course of sarcoidosis, are capable of inducing the release of monocyte chemoattractant protein-1 and IL-8 by pneumocytes II. In sarcoidosis the activation of these cells is indicated by their production of TGF-β,\textsuperscript{210} their release of KL-6, a mucin-like protein glycoprotein,\textsuperscript{211} and their up-regulation of HLA-DR expression.\textsuperscript{212}

Although the involvement of pneumocytes II in the immunopathology of interstitial lung diseases has been demonstrated, their role in sarcoidosis
remains to be elucidated. A number of methodological problems impede their investigation. The maintenance of pneumocytes II in tissue culture is difficult\textsuperscript{213} and they can only be obtained from patients with interstitial lung diseases when a diagnostic open lung biopsy, currently a rare diagnostic procedure, is indicated. The available methods to isolate pneumocytes II require a large cell input to obtain sufficient numbers of pneumocytes II for cell biological experiments. For future research the preparation techniques need to be miniaturized to work with thoraco-scopically obtained lung biopsies or even with transbronchial biopsies.

In respiratory physiology the most important product of pneumocytes II is the surface-active material of the alveolar lining fluid, called surfactant, which reduces surface tension at the alveolar surface, promotes lung expansion on inspiration and prevents lung collapse on expiration. It is composed of phospholipids and four apoproteins, named SP-A, B, C, and D.\textsuperscript{214} Surfactant as a whole and especially the apoproteins have pro- and anti-inflammatory properties. In the presence of surfactant bacteria become opsonized,\textsuperscript{215} macrophages are attracted by chemotaxis\textsuperscript{47} and their phagocytosis is stimulated.\textsuperscript{216} On the other hand surfactant protects the lower respiratory tract from harmful effects of the immune system by scavenging radical oxygen intermediates\textsuperscript{217,218} and by inhibiting alveolar macrophage activation, e.g. the rise of intracellular calcium after activation is blocked by sP-a\textsuperscript{44} and the activation of the genes of proinflammatory cytokines is inhibited on the transcriptional level.\textsuperscript{219}

In interstitial lung diseases including sarcoidosis multiple alterations in the composition of surfactant are observed\textsuperscript{220,221} resulting in a loss of macrophage inhibiting capabilities\textsuperscript{44} or even stimulation of these cells.\textsuperscript{220} Artificial surfactants with different amounts of apoproteins and phospholipids are now available as drugs can be delivered by inhalation.\textsuperscript{222} A better understanding of the immunomodulatory capabilities of surfactant might open new therapeutic approaches for the treatment of chronic inflammation of the lower respiratory tract.

### Conclusion

Studies of BAL cells, T-cell clones, lymph nodes and lung parenchyma have advanced our understanding of the immunopathogenesis of interstitial lung diseases and, in particular, sarcoidosis. New clinical serum parameters allowing to monitor certain aspects of sarcoid immunopathogenesis have been delineated from this knowledge. Moreover, in the course of these investigations it became clear that the pulmonary immune reaction is compartmentalized. The activated cells, their mediators, and the corresponding control mechanisms are confined to the lung\textsuperscript{50,63,156,149,153,156,161,169,193} although with sophisticated methods evidence for immune cell activation has been obtained from specimens of the peripheral blood.\textsuperscript{137,223} Thus, organ-specific immunoregulatory mechanisms render the lung into a specialized immunological environment with a low responsiveness at the site of first antigen contact.\textsuperscript{30,159} In spite of the fact that effective immune stimulation takes place in the lower respiratory tract only few of the activated cells undergo mitosis\textsuperscript{151,153} but leave the lung\textsuperscript{160,224} and proliferate in the regional lymph nodes.\textsuperscript{161,225}

Studies of the pulmonary immune response in health and disease gave further support for this concept of compartmentalization. The immunoglobulin production of B-lymphocytes of the lung continues over a relatively long time after the lung is transplanted and seems to function independent of the immune system of the graft.\textsuperscript{226} Immunophenotyping of the T-cells on the alveolar epithelial surface of healthy individuals revealed that these cells are permanently activated and exchange only very slowly with the blood pool\textsuperscript{150,227} explaining the delayed changes of the diseased immunophenotypes when the patients are under therapy.\textsuperscript{228} Local instillation of bacteria into the lung leads to neutrophil and cytokine accumulation in the area of instillation. If, however, the instillation dose is higher and meditators accumulate in the noninstilled parts of the lung as well and a systemic cytokine release is observed\textsuperscript{229} indicating that the reactions to overwhelming injury cannot be confined to the lung as it can be seen from the systemic reaction, e.g. fever and myalgia, in sarcoidosis and other lung diseases.

### References


252 Mediators of Inflammation Vol 5 1996


Mediators of Inflammation Vol 5 1996 253

Sarcoidosis
J. Müller-Quernheim


Submit your manuscripts at
http://www.hindawi.com